sativex

Phytanix Bio, a preclinical stage pharmaceutical company, has released an updated investor deck. The presentation showcases a business strategy aimed at developing new cannabinoid-based pharmaceuticals. The company, which has ties to historical pharmaceutical developments in the cannabis industry,...

Chain Bridge I (NASDAQ:CBRG) announced on Monday the acquisition of Phytanix Bio, a pharmaceutical company specializing in the development of therapeutics based on cannabinoid and cannabinoid-like molecules. The transaction, valued at $58 million, also includes the assumption of preferred stock and...

German Regional Government Isn't Onboard With National Marijuana Legalization Plan Germany's Health Minister Karl Lauterbach recently submitted a draft bill to legalize recreational cannabis possession, cultivation and social clubs. The proposal seeks to allow adults to possess up to 25...

Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical trials. Spasticity is characterized by increased muscle stiffness and spasms, which can be...

Can a cannabis-based medicine help treat aggressive brain tumors? Scientists in the UK are getting closer to answering that question. Ongoing lab research is about to become real-world as the project just recruited its first volunteers. The ARISTOCRAT study on the effectiveness of Sativex, a...

The Swiss government confirmed that it will remove limitations on medical marijuana use, starting August 1st, 2022.  Medical marijuana patients are required to seek exceptional authorization from the health ministry to get medical cannabis prescriptions, which causes needless delays...

In cancer patients, cannabinoids have primarily been used as a part of palliative care to help alleviate pain, reduce inflammation, relieve nausea and stimulate appetite. However, with the field evolving rapidly over the past years, thanks to both legislative efforts and push from marijuana...

Patients suffering from glioblastoma, the most common, deadly and extremely aggressive type of brain cancer, may have a chance of living longer if Sativex, a cannabis-based mouth spray, proves effective in treating recurrent brain tumors. Cancer charities and the UK's National...

Canadian cannabis startup VerdeMed has been expanding across Latin America. Over the last few months, the company started selling CBD products to select patients in Brazil, won four public bids to supply local governments with cannabis-derived products, and closed a deal to supply its products...

GW Pharmaceuticals plc (NASDAQ: GWPH) said Monday it will obtain exclusive rights for the commercialization of Sativex in the U.K. from Bayer AG (OTC: BAYRY). Sativex is an oromucosal spray with the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) in a 1-to-1 ratio....

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced Sunday that two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service.  What Happened Epidiolex, known as...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported its financial results Tuesday for the first quarter of fiscal 2019. The company reported revenue growth of  67.5 percent. One highlight: the report includes sales of the company's Epidiolex drug, which last year became the first cannabis-based...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported financial results for its fiscal fourth quarter 2018. Compared to analysts' consensus estimates, the company reported a better-than-expected net loss, but its top line missed the expectations. What Happened For the quarter ended Sept. 30, GW...

Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy market and its cannabinoid science platform. The Analyst Leerink's Marc Goodman...

2017 had a bullish tone, as assets across categories shone the brightest, although cryptocurrency could be singled out as the standout performer. Marijuana stocks also joined the party, as reflected by the 18.5-percent advance by the U.S. Marijuana Index. Momentum Extending Into The New Year...